PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

A critical appraisal of PCSK9 inhibitors: PCSK9 monoclonal antibodies versus small interfering RNA Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders

Latest News Updates

14th Closed Scientific Expert Meeting of the Editorial Board

Virtual meeting, 9th June 2021 (Educational supporters)

PCSK9 inhibition: The evolving treatment paradigm post-MI – A perspective from Professor Gregory Schwartz

PCSK9 inhibition: The evolving treatment paradigm post-MI – A perspective from Professor Gregory Schwartz

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Gregory Schwartz

Posted on 23 August 2021 | Posted in 14th Closed Scientific Expert Meeting of the Editorial Board

PCSK9 inhibition: The evolving treatment paradigm post-MI – A perspective from Professor Robert Giugliano

PCSK9 inhibition: The evolving treatment paradigm post-MI – A perspective from Professor Robert Giugliano

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Robert Giugliano

Posted on 23 August 2021 | Posted in 14th Closed Scientific Expert Meeting of the Editorial Board

Low lipoprotein(a): Is there any potential risk?

Low lipoprotein(a): Is there any potential risk?

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Anne Langsted

Posted on 7 July 2021 | Posted in Hot topics, 14th Closed Scientific Expert Meeting of the Editorial Board

Cholesterol crystals, plaque stability and ASCVD

Cholesterol crystals, plaque stability and ASCVD

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor John Chapman

Posted on 6 July 2021 | Posted in Hot topics, 14th Closed Scientific Expert Meeting of the Editorial Board

Bempedoic acid: An update on the trials

Bempedoic acid: An update on the trials

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Erik Stroes

Posted on 7 July 2021 | Posted in 14th Closed Scientific Expert Meeting of the Editorial Board

Attaining LDL cholesterol goal: Triple combination strategies

Attaining LDL cholesterol goal: Triple combination strategies

Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Michel Farnier

Posted on 6 July 2021 | Posted in 14th Closed Scientific Expert Meeting of the Editorial Board

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved